The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer

Eur J Med Res. 2023 Nov 1;28(1):475. doi: 10.1186/s40001-023-01382-2.

Abstract

Thyroid cancer (TC) is the most predominant malignancy of the endocrine system, with steadily growing occurrence and morbidity worldwide. Although diagnostic and therapeutic methods have been rapidly developed in recent years, the underlying molecular mechanisms in the pathogenesis of TC remain enigmatic. The N6-methyladenosine(m6A) RNA modification is designed to impact RNA metabolism and further gene regulation. This process is intricately regulated by a variety of regulators, such as methylases and demethylases. Aberrant m6A regulators expression is related to the occurrence and development of TC and play an important role in drug resistance. This review comprehensively analyzes the effect of m6A methylation on TC progression and the potential clinical value of m6A regulators as prognostic markers and therapeutic targets in this disease.

Keywords: N6-Methyladenosine; Prognosis; Progression; Thyroid cancer; Treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • RNA / genetics
  • Thyroid Neoplasms* / genetics

Substances

  • RNA